Skip to content
DraconiticResearch
Search Sources API
197,761 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BYBMC Ophthalmology

Progressive intraocular inflammation with anterior scleritis following intravitreal Faricimab for neovascular age-related macular degeneration: a case report

  • Ching-Hua Hsu1
  • Acer I-Hung Chen1
  • Chien-Hsiung Lai2
  • Nan-Ni Chen2
  1. 1Department of Medical Education, Chiayi Chang Gung Memorial Hospital
  2. 2Department of Ophthalmology, Chiayi Chang Gung Memorial Hospital
Read full textDOICite

Abstract

Background To report a rare and instructive case of intraocular inflammation following intravitreal Faricimab (Vabysmo) injection that progressed to anterior scleritis despite early intervention. While Faricimab is widely used for neovascular age-related macular degeneration (nAMD), understanding its potential for delayed, progressive inflammatory complications is crucial for clinical vigilance. Case presentation A 74-year-old Asian male with nAMD developed intraocular inflammation following his fifth intravitreal injection of Faricimab, after four prior uneventful injections. The patient initially presented with corneal edema, anterior uveitis, and elevated intraocular pressure (IOP). Although initial treatment with topical corticosteroids and IOP-lowering agents led to partial improvement, the inflammation subsequently progressed, manifesting as persistent vitritis and the development of anterior scleritis. Escalation to systemic corticosteroid therapy was required, which resulted in complete resolution of the inflammation. Faricimab was permanently discontinued, and the patient was successfully switched to Aflibercept (Eylea) without further complications. Conclusions This case highlights that initially mild anterior segment inflammation following Faricimab injection can progress to more severe ocular inflammation, such as scleritis, despite early topical therapy. Clinicians should maintain close monitoring and a low threshold for escalating to systemic treatment to achieve complete resolution and safeguard visual outcomes.

Related

  1. Noninfectious intraocular inflammation with hypopyon after intravitreal aflibercept 8 mg injection for neovascular age-related macular degeneration: a case report
    Hiroyuki Kamao, Ryutaro Hiraki, Date Yuto +2
    BMC OphthalmologyPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  2. Intravitreal Nilotinib Reduces Fibroblast Growth Factor-2 Levels in a Rat Model of Dispase-Induced Intraocular Inflammation
    Hakan Yildirim, Hakan Veli Savaş, Mehmet Balbaba +3
    Journal of Vitreoretinal DiseasesPeer-reviewedLicence not statedFull text1 citedGeneral medicinePMC
  3. Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.
    Jules Fricker, Lucas Sejournet, Jules Prange +11
    Ophthalmology and therapyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCDOAJ
  4. Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration
    Huan Ju, Xuan-Heng Ding, Ling-Yi Jin +4
    International Journal of OphthalmologyPeer-reviewedCC BY-NC-NDFull textGeneral medicinePMC
  5. Comparative Study on the Efficacy of Intravitreal and Subconjunctival Simultaneous Injection of Conbercept Followed by Trabeculectomy Versus Intravitreal Injection of Conbercept Followed by Trabeculectomy Combined With 5-Fluorouracil (5-FU) in the Treatment of Neovascular Glaucoma (NVG).
    Peiyu Xing, Wei Qu, Yong Zhang +5
    Journal of ophthalmologyPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{hsu2026progressive,
  title = {{Progressive intraocular inflammation with anterior scleritis following intravitreal Faricimab for neovascular age-related macular degeneration: a case report}},
  author = {Ching-Hua Hsu and Acer I-Hung Chen and Chien-Hsiung Lai and Nan-Ni Chen},
  journal = {BMC Ophthalmology},
  year = {2026},
  month = jul,
  doi = {10.1186/s12886-026-05143-7},
  url = {https://doi.org/10.1186/s12886-026-05143-7},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Progressive intraocular inflammation with anterior scleritis following intravitreal Faricimab for neovascular age-related macular degeneration: a case report
AU  - Ching-Hua Hsu
AU  - Acer I-Hung Chen
AU  - Chien-Hsiung Lai
AU  - Nan-Ni Chen
PY  - 2026
DA  - 2026/07/01
JO  - BMC Ophthalmology
DO  - 10.1186/s12886-026-05143-7
UR  - https://doi.org/10.1186/s12886-026-05143-7
AB  - Background To report a rare and instructive case of intraocular inflammation following intravitreal Faricimab (Vabysmo) injection that progressed to anterior scleritis despite early intervention. While Faricimab is widely used for neovascular age-related macular degeneration (nAMD), understanding its potential for delayed, progressive inflammatory complications is crucial for clinical vigilance. Case presentation A 74-year-old Asian male with nAMD developed intraocular inflammation following his fifth intravitreal injection of Faricimab, after four prior uneventful injections. The patient initially presented with corneal edema, anterior uveitis, and elevated intraocular pressure (IOP). Although initial treatment with topical corticosteroids and IOP-lowering agents led to partial improvement, the inflammation subsequently progressed, manifesting as persistent vitritis and the development of anterior scleritis. Escalation to systemic corticosteroid therapy was required, which resulted in complete resolution of the inflammation. Faricimab was permanently discontinued, and the patient was successfully switched to Aflibercept (Eylea) without further complications. Conclusions This case highlights that initially mild anterior segment inflammation following Faricimab injection can progress to more severe ocular inflammation, such as scleritis, despite early topical therapy. Clinicians should maintain close monitoring and a low threshold for escalating to systemic treatment to achieve complete resolution and safeguard visual outcomes.
SN  - 1471-2415
ER  -